Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3733_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Preface
- •Acknowledgments
- •Section A Introduction to Embolic Agents
- •Section B Coils and Plugs
- •2 Pushable Coils
- •3 Detachable Coils
- •4 Vascular Plugs
- •5 Gelatin Sponge
- •6 Polyvinyl Alcohol Particles
- •7 Spherical Embolic Agents
- •Section C Particulate Agents
- •8 Drug-Eluting Beads
- •Section D Liquid Agents
- •9 Glue
- •10 EVOH/DMSO in Peripheral Application
- •11 Sclerosing Agents
- •Section E Catheters
- •12 Catheters and Catheterization Techniques
- •13 Vascular Malformations
- •14 Intracranial Aneurysms
- •Section B Head and Neck Embolization
- •15 Epistaxis
- •16 Vascular Tumors
- •17 Carotid Blowout Syndrome
- •Section C Thoracic Embolization
- •18 Hemoptysis
- •19 Pulmonary Arteriovenous Fistulas
- •20 Chest Tumors
- •Section D Trauma Embolization
- •22 Thoracoabdominal Trauma
- •23 Pelvic Trauma
- •24 Extremity Trauma
- •25 Spine and Bone Trauma
- •26 Iatrogenic Lesions
- •Section E Peripheral Embolization
- •27 Peripheral Vascular Malformations

TECHNIQUE
In general, spherical microspheres are packaged in a syringe consisting of a
defined volume of embolic and normal saline. For administration, contrast
material is added to make the solution radiopaque. A maximum saline-tocontrast ratio of 1:1 is recommended. Typically, gentle swirling of the
solution is recommended before delivery; this and time will allow for the
microspheres to be adequately suspended in the saline and contrast solution.
To-and-fro aspiration between two syringes connected via a three-way
stopcock is both unnecessary and not recommended as it may damage the
microspheres.
Once the microspheres have been prepared, they are typically
administered through a microcatheter under fluoroscopic guidance. Although
the catheter selection can be based on the size of the microspheres being used
for any given procedure, these microspheres tend to be more easily
administered with microcatheters having an inner diameter of 0.027 to 0.028
in as opposed to smaller microcatheters.
One limitation of the trisacryl gelatin microspheres is that they are clear,
which can make preparation difficult and visual confirmation of delivery
from the syringe challenging. A subsequent product used elemental gold to
stain the microspheres, which improved visualization. However, the addition
of elemental gold resulted in a greater degree of inflammation after
embolization, which ultimately led to the discontinuation of this product.
17
CLINICAL APPLICATIONS
Beaujeux et al.10 reported the initial clinical success of using trisacryl gelatin
microspheres on 105 patients with tumors or arteriovenous malformations in
the head, neck, or spine. Since this initial report, all of the available embolic
microspheres have been rapidly incorporated into present-day embolization
procedures and have been used successfully for various indications that are
suitable for a particulate embolic agent.
These microspheres have had particularly notable success when used for

uterine artery embolization (UAE) to treat symptomatic uterine fibroids.
Although the success seen with the use of trisacryl gelatin microspheres has
set the standard for subsequent comparative clinical trials,
18
each of the
available embolic microspheres have demonstrated high clinical success and
fibroid infarction rates in association with this procedure.
19
,20
However, all of
the attention paid to this procedure has brought to light how the different
characteristics of these embolic microspheres can affect clinical outcomes
and as a result has improved our understanding of these agents. For example,
Contour SE Microspheres have been shown to be less effective for this
procedure than other agents.
21
,22
This is felt to be due to the differences in
compressibility, deformability, and elasticity of this particular product when
compared to the other available embolic microspheres, which was previously
not appreciated until the differences in clinical outcomes were recognized.
NEXT GENERATION MICROSPHERES
Resorbable Microspheres
In theory, there is an inherent appeal to the concept of resorbable
microspheres. All embolization procedures are being performed for certain
indications, and if the goal of the procedure can be accomplished without
implanting a permanent foreign body into the patient, then why would not
that be preferred? In 2007, Laurent
2
suggested that the ideal resorbable
microsphere would have four characteristics: it would have controlled
resorption time, it would cause only a limited local inflammatory response, it
would be associated with a complete functionality of the target vascular bed,
and it would be loadable. If these expectations could be met, then one could
be assured that the target pathology would be definitively and appropriately
treated while leaving open the possibility that the target organ would fully
recover and suffer no long-term effects from the embolization procedure.
There has been significant effort to develop bioresorbable microspheres
in recent years. Nowadays, degradable starch microspheres have been
evaluated for several years23 and are commercially available (EmboCept S;

PharmaCept, Berlin, Germany). These microspheres have been used for liverdirected tumor therapy.
24,25
The problem is that the starch microspheres are
only available in a 50-μm diameter size and have a very short half-life,
limiting their acceptance for the more common applications requiring
particulate embolization.
Weng et al.
26
have done much work with bioresorbable hydrogel
microspheres prepared from carboxymethylcellulose and chitosan. Chitosan
(N-acetylglucosamine) is a linear polysaccharide derived from chitin after
deacetylation.27 Introducing carboxymethyl groups into the chitosan produces
chitosan derivatives that are readily soluble in a physiologic pH.28 The
carboxymethyl chitosan can then be cross-linked with oxidized
carboxymethylcellulose to form microspheres through an inverse emulsion
method. These microspheres are degraded by lysozyme into glucosamine,
which can be absorbed completely by the body. The degradation time appears
to depend on the parameters of microsphere preparation, specifically on the
degree of cross-linking density. These microspheres do not aggregate due to
low coefficient of surface friction. In vivo evaluation comparing these
microspheres with trisacryl gelatin microspheres has been performed with
renal embolization in a rabbit model.29 The performance of the two agents
was similar in terms of the mean size of the vessels occluded with the two
microspheres. These microspheres were biocompatible and well tolerated,
with a mild tissue reaction and no evidence of vessel wall disruption. The
authors did demonstrate that preparing the resorbable microspheres with a
higher cross-linking density makes the spheres more rigid, which
subsequently causes a more proximal embolization. Of note, the carboxylic
groups in the microsphere matrix and their highly porous internal structure
may allow for loading and release of positively charged drugs such as
doxorubicin hydrochloride.
28
Microspheres consisting of poly(lactic-co-glycolic acid) (PLGA) coated
with type I bovine fibrillar collagen have also been evaluated (Occlusin 500
Artificial Embolization Device; IMBiotechnologies Ltd., Edmonton, Alberta,
Canada). These noncompressible microspheres create a vascular occlusion
mechanically and by binding platelets. An in vivo evaluation of these

microspheres has been performed with UAE in a sheep model.30 In this
study, the effects of embolization with 150- to 212-μm PLGA microspheres
were compared with the effects after embolization with trisacryl gelatin
microspheres. At 6 months, none of the embolic material in the animals
embolized with PLGA microspheres was detectable. At 12 months, all
uterine arteries treated with the PLGA microspheres were recanalized or in
the process of being recanalized; recanalized vessels were histologically
indistinguishable from untreated vessels. The arteries treated with trisacryl
gelatin microspheres remained occluded at 12 months.
There are other agents in various stages of development. Water-soluble
PVA microspheres have been developed and evaluated in a pig kidney
model.31 The duration of arterial occlusion using these microspheres is
possibly related to the degree of saponification of PVA. Microspheres
manufactured from hydrophilic methacrylate monomer copolymerized with
degradable cross-linkers have been evaluated as well.
32
Visible Microspheres
An additional point of development for embolic microspheres is in the area of
radiographic visibility. Nowadays, microspheres used for embolization are
not radiographically visible and must therefore be mixed with contrast to be
seen under fluoroscopy during delivery. An agent that could be visualized
under fluoroscopy as well as under computed tomography (CT) or magnetic
resonance (MR) imaging would be helpful to assess particle distribution
during embolization and to assess nontarget embolization.33 Work has been
done in this area by Sharma et al.34 who demonstrated that PVA hydrogel
microspheres (LC Beads; Biocompatibles UK Ltd., Farnham, Surrey, United
Kingdom) loaded with Lipiodol are visible on fluoroscopy and CT. Bartling
et al.35 developed an embolization particle that consists of an x-ray visible,
iodine-containing core and an MRI-visible, paramagnetic iron oxide–based
coating. Stampfl et al.33 have modified a Polyzene-F–coated embolic
microsphere with barium sulfate and iodine as well as with iron oxide,
making them visible on radiography, CT, and MRI. This continues to be an

ongoing area for development.
TIPS AND TRICKS
• All spherical embolic agents are not the same. Compressibility and
other characteristics may significantly impact the clinical results
achieved with each agent.
• The use of larger inner diameter microcatheters (≥0.027 in) is
recommended to ease administration of embolic microspheres.
• The best way to obtain an optimal suspension of embolic
microspheres after the addition of contrast to the saline and
microsphere mix is with time; to-and-fro aspiration between two
syringes via a three-way stopcock may damage the microspheres.
CONCLUSION
The popularity of embolic microspheres has increased significantly in recent
years, becoming a category of embolic agent that is safely and effectively
used for various clinical applications. During this time, significant research
has been done in the area of embolic microspheres, enabling us to obtain a
good understanding of their characteristic and of their clinical strengths and
limitations. This has all resulted in continuing development of new spherical
products that are not limited to drug elution. In time, the attention being paid
to this area will inevitably enhance the drug-eluting abilities of new and
existing microspheres and lead to the development of both resorbable and
visible microspheres. Each of these new characteristics will improve our
ability to treat a growing number of patients using spherical embolic agents.
REFERENCES
1. Tadavarthy SM, Knight L, Ovitt TW, et al. Therapeutic transcatheter

arterial embolization. Radiology. 1974;111:13–16.
2. Laurent A. Microspheres and nonspherical particles for embolization.
Tech Vasc Interv Radiol. 2007;10:248–256.
3. Laurent A, Beaujeux R, Wasset M, et al. Trisacryl gelatin microspheres
for therapeutic embolization, I: development and in vitro evaluation. Am
J Neuroradiol. 1996;17:533–540.
4. Obrenovitch A, Maintier C, Sene C, et al. Microcarrier culture of
fibroblastic cells on modified trisacryl beads. Biol Cell. 1982;46:249–
256.
5. Derdeyn CP, Graves VG, Salamant MS, et al. Collagen-coated acrylic
microspheres for embolotherapy: in vivo and in vitro characteristics. Am
J Neuroradiol. 1997;18:647–653.
6. Andrews RT, Binket CA. Relative rates of blood flow reduction during
transcatheter arterial embolization with tris-acryl gelatin microspheres or
polyvinyl alcohol: quantitative comparison in a swine model. J Vasc
Interv Radiol. 2003;14:1311–1313.
7. Laurent A, Wassef M, Saint Maurice JP, et al. Arterial distribution of
calibrated tris-acryl gelatin and polyvinyl alcohol microspheres in a
sheet kidney model. Invest Radiol. 2006;41:8–14.
8. Laurent A, Wassef M, Namur J, et al. Arterial distribution of calibrated
tris-acryl gelatin and polyvinyl alcohol embolization microspheres in
sheep uterus. Cardiovasc Intervent Radiol. 2010;33:995–1000.
9. Siskin GP, Dowling K, Virmani R, et al. Pathologic evaluation of a
spherical polyvinyl alcohol embolic agent in a porcine model. J Vasc
Interv Radiol. 2003;14:89–98.
10. Beaujeux R, Laurent A, Wassef M, et al. Trisacryl gelatin microspheres
for therapeutic embolization, II: preliminary clinical evaluation in
tumors and arteriovenous malformations. Am J Neuroradiol.
1996;17:541–548.
11. Laurent A, Wassef M, Namur J, et al. Recanalization and particle
exclusion after embolization of uterine arteries in sheep: a long-term
study. Fertil Steril. 2009;91:884–892.
12. Verret V, Wassef M, Pelage JP, et al. Influence of degradation on

inflammatory profile of polyphosphazine coated PMMA and trisacryl
gelatin microspheres in a sheep uterine artery embolization model.
Biomaterials. 2011;32:339–351.
13. Jayakrishnan A, Chittambara Thanoo B, Rathinam K, et al. Hydrogel
microspheres from crosslinked poly (methylmethacrylate): synthesis and
biocompatibility study. Bull Mater Sci. 1989;12:17–25.
14. Stampfl S, Stampfl U, Bellemann N, et al. Biocompatibility and
recanalization characteristics of hydrogel microspheres with Polyzene-F
as polymer coating. Cardiovasc Intervent Radiol. 2008;31:799–806.
15. Richter GM, Stampfl U, Stampfl S, et al. A new polymer concept for
coating of vascular stents using PTFEP
(poly(bis(trifluoroethoxy)phosphazene)) to reduce thrombogenicity and
late in-stent stenosis. Invest Radiol. 2005;40:210–218.
16. Verret V, Homayra Ghegediban S, Wassef M, et al. The arterial
distribution of Embozene and Embosphere microspheres in sheep
kidney and uterine embolization models. J Vasc Interv Radiol.
2011;22:220–228.
17. Richard HM, Siskin GP, Stainken BF. Endometritis after uterine artery
embolization with gold-colored gelatin microspheres. J Vasc Interv
Radiol. 2004;15:406–407.
18. Spies JB, Cornell C, Worthington-Kirsch R, et al. Long-term outcome
from uterine fibroid embolization with tris-acryl gelatin microspheres:
results of a multicenter study. J Vasc Interv Radiol. 2007;18:203–207.
19. Worthington-Kirsch RL, Siskin GP, Hegener P, et al. Comparison of the
efficacy of the embolic agents acrylamido polyvinyl alcohol
microspheres and tris-acryl gelatin microspheres for uterine artery
embolization for leiomyomas: a prospective randomized controlled trial.
Cardiovasc Intervent Radiol. 2011;34:493–501.
20. Smeets AJ, Nijenhuis RJ, Jan van Rooij W, et al. Embolization of
uterine leiomyomas with Polyzene F-coated hydrogel microspheres:
initial experience. J Vasc Interv Radiol. 2010;21:1830–1834.
21. Siskin GP, Beck A, Schuster M, et al. Leiomyoma infarction after
uterine artery embolization: a prospective randomized study comparing

tris-acryl gelatin microspheres versus polyvinyl alcohol microspheres. J
Vasc Interv Radiol. 2008;19:58–65.
22. Yu SC, Lok I, Ho SS, et al. Comparison of clinical outcomes of trisacryl microspheres versus polyvinyl alcohol microspheres for uterine
artery embolization for leiomyomas: results of a randomized trial. J
Vasc Interv Radiol. 2011;22:1229–1235.
23. Forsberg JO. Transient blood flow reduction induced by intra-arterial
injection of degradable starch microspheres. Experiments on rats. Acta
Chir Scand. 1978;144:275–281.
24. Nishiofuku H, Tanaka T, Matsuoka M, et al. Transcatheter arterial
chemoembolization using cisplatin powder mixed with degradable
starch microspheres for colorectal liver metastases after FOLFOX
failure: results of a phase I/II study. J Vasc Interv Radiol. 2013;24:56–
65.
25. Yamasaki T, Saeki I, Harima Y, et al. Effect of transcatheter arterial
infusion chemotherapy using iodized oil and degradable starch
microspheres for hepatocellular carcinoma. J Gastroenterol.
2012;47:715–722.
26. Weng L, Le HC, Talaie R, et al. Bioresorbable hydrogel microspheres
for transcatheter embolization: preparation and in vitro evaluation. J
Vasc Interv Radiol. 2011;22:1454–1470.
27. Alves da Silva ML, Crawford A, Mundy JM, et al. Chitosan/polyesterbased scaffolds for cartilage tissue engineering: assessment of
extracellular matrix formation. Acta Biomater. 2010;6:1149–1157.
28. Weng L, Rostamzadeh P, Nooryshokry N, et al. In vitro and in vivo
evaluation of biodegradable embolic microspheres with tunable
anticancer drug release. Acta Biomaterialia. 2013;9:6823–6833.
29. Weng L, Rusten M, Talaie R, et al. Calibrated bioresorbable
microspheres: a preliminary study on the level of occlusion and arterial
distribution in a rabbit kidney model. J Vasc Interv Radiol.
2013;24:1567–1575.
30. Owen RJ, Nation PN, Polakowski R, et al. A preclinical study of the
safety and efficacy of Occlusin™ 500 Artificial Embolization Device in

sheep. Cardiovasc Intervent Radiol. 2012;35:636–644.
31. Shomura Y, Tanigawa N, Shibutani M, et al. Water-soluble polyvinyl
alcohol microspheres for temporary embolization: development and in
vivo characteristics in a pig kidney model. J Vasc Interv Radiol.
2011;22:212–219.
32. Louguet S, Verret V, Bédouet L, et al. Poly(ethylene glycol)
methacrylate hydrolyzable microspheres for transient vascular
embolization. Acta Biomater. 2014;10:1194–1205.
33. Stampfl U, Sommer CM, Bellemann N, et al. Multimodal visibility of a
modified Polyzene-F coated spherical embolic agent for liver
embolization: feasibility study in a porcine model. J Vasc Interv Radiol.
2012;23:1225–1231.
34. Sharma KV, Dreher MR, Tang Y, et al. Development of “imageable”
beads for transcatheter embolotherapy. J Vasc Interv Radiol.
2010;21:865–876.
35. Bartling SH, Budjan J, Aviv H, et al. First multimodal embolization
particles visible on x-ray/computed tomography and magnetic resonance
imaging. Invest Radiol. 2011;46:178–186.

T
8
Drug-Eluting Beads
Matthew E. Anderson • Sanjeeva P. Kalva
he introduction of drug-eluting beads represents a shift in the
principal way in which chemotherapeutic agents are delivered,
concentrated, and maintained within tumor during transarterial
chemoembolization. Rather than using particles and/or Ethiodol to occlude
the arterial flow in an attempt to keep the chemotherapy in the neoplasm, the
particle (the bead) itself is the carrier of the chemotherapeutic agent. Once the
particle is trapped within the neoplasm, it serves as the depot, allowing for
sustained release of the drug with reduced systemic drug concentrations. This
also reduces associated side effects while sustaining high chemotherapeutic
concentrations within tumor. The concept of drug delivery through
microparticles using various nondegradable and degradable synthetic
polymers (such as polyglycolic acid, polyhydroxybutyrate, or ethylene vinyl
acetate) or natural materials (albumin, gelatin, chitosan, or alginate) for
carrying drugs such as doxorubicin, mitomycin C, cisplatin, methotrexate,
and paclitaxel was described as early as 1983.1 However, commercially
available drug-capable beads were not developed until 2004.
2
Соседние файлы в папке Библиотека им академика М.И. Перельмана
